Morgan Stanley assumed coverage of Cullinan Therapeutics (CGEM) with an Overweight rating and a price target of $35, down from $38. The firm sees upside potential for CLN-978 with the upcoming initial clinical data and is positive on the pipeline, focusing on the near-term zipalertinib presentation and CLN-619 data, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Therapeutics: Promising Pipeline and Upcoming Catalysts Justify Buy Rating
- Promising Pipeline and Financial Stability Drive Buy Rating for Cullinan Management
- Cullinan Management: Strong Financial Position and Promising Clinical Developments Drive Buy Rating
- Cullinan Management Faces Uncertainty Amid Market Forecast Challenges and Competitive Pressures
- Cullinan Therapeutics Reports 2024 Financial Results and Updates
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue